Compare · AZN vs EWTX
AZN vs EWTX
Side-by-side comparison of AstraZeneca PLC (AZN) and Edgewise Therapeutics Inc. (EWTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and EWTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $277.21B, about 61.2x EWTX ($4.53B).
- AZN has been more active in the news (23 items in the past 4 weeks vs 12 for EWTX).
- AZN has more recent analyst coverage (25 ratings vs 17 for EWTX).
- Company
- AstraZeneca PLC
- Edgewise Therapeutics Inc.
- Price
- $176.39-1.32%
- -
- Market cap
- $277.21B
- $4.53B
- 1M return
- +5.89%
- -
- 1Y return
- +100.84%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 23
- 12
- Recent ratings
- 25
- 17
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Latest AZN
- Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Latest EWTX
- CMO Joanne M. Donovan sold $38,840 worth of shares (854 units at $45.48), decreasing direct ownership by 9% to 8,139 units (SEC Form 4)
- SEC Form 144 filed by Edgewise Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.
- Chief Financial Officer Nofi Michael converted options into 10,937 shares and sold $201,787 worth of shares (4,442 units at $45.43) (SEC Form 4) to cover withholding tax
- /C O R R E C T I O N - Edgewise Therapeutics/
- Edgewise Therapeutics to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.
- Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
- SEC Form 10-Q filed by Edgewise Therapeutics Inc.
- Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits